doi: 10.1002/osp4.70033, 28 DossatA
A survey of people in different age groups asked whether respondents had ever used GLP-1 medications and, if so, what they had used them for
The mean 9.4% BW reduction exhibited by patients treated with OW semaglutide 2.4 mg might partially explain the HF benefit observed in this trial 84 , as previously demonstrated for treatments leading to at least 10% weight loss 87
In one recent case report, an ALS patient showed clinical improvement after receiving FMT, with better scores on the ALS Functional Rating Scale and lower levels of inflammation-related markers like CRP and IL-6 (Yan et al., 2024)
The triple-receptor mechanism (GLP-1, GIP, and glucagon) addresses multiple metabolic pathways that become disrupted during hormonal transition, making it particularly well-suited for menopausal weight management